Filing Flows › Haemonetics (HAE) › Q2 FY27 › vs Q2 FY26
Haemonetics (HAE) Q2 FY27 vs Q2 FY26 (year over year)
Haemonetics's revenue rose $30.4M (+9%) from $327M in Q2 FY26 to $358M in Q2 FY27. The biggest changes: Apheresis +$23.0M (+13%); MedSurg +$7.5M (+5%). Gross margin 61.7% against 59.5% (+2.3 pts).
Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%, net earnings $46.3M, operating cash flow $128M. The chart draws each line against Q2 FY26, the increases inside each band.
Margins
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Gross margin | 61.7% | 59.5% | +2.3 pts |
| Operating margin | 21.0% | 17.9% | +3.1 pts |
| Net margin | 12.9% | 11.8% | +1.1 pts |
| Free cash flow margin | 31.7% | 32.5% | -0.8 pts |
Every line
| Line | Q2 FY27 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Apheresis | $205M | $182M | $23.0M | +13% |
| MedSurg | $153M | $145M | $7.5M | +5% |
| Revenue | $358M | $327M | $30.4M | +9% |
| Gross profit | $221M | $195M | $26.2M | +13% |
| Cost of revenue | $137M | $133M | $4.3M | +3% |
| Operating profit | $75.1M | $58.5M | $16.6M | +28% |
| Operating expenses | $146M | $136M | $9.5M | +7% |
| Pre-tax earnings | $62.9M | $51.3M | $11.6M | +23% |
| Other expense, net | $12.3M | $7.2M | $5.1M | +70% |
| Research & development | $17.0M | $14.9M | $2.2M | +15% |
| SG&A | $118M | $102M | $16.7M | +16% |
| Other operating costs | $10.4M | $19.8M | −$9.4M | -47% |
| Net earnings | $46.3M | $38.7M | $7.6M | +20% |
| Income tax | $16.6M | $12.6M | $4.0M | +31% |
| Depreciation & amortization | $27.8M | $28.3M | −$495K | -2% |
| Share-based compensation | $10.2M | $7.6M | $2.6M | +35% |
| Working capital & other | $43.8M | $36.8M | $7.0M | +19% |
| Operating cash flow | $128M | $111M | $16.8M | +15% |
| Free cash flow (OCF − capex) | $113M | $106M | $7.0M | +7% |
| Capital expenditures | $14.8M | $5.0M | $9.8M | +194% |
Questions
How much did Haemonetics's revenue grow year over year in Q2 FY27?
Haemonetics's revenue rose $30.4M (+9%) from $327M in Q2 FY26 to $358M in Q2 FY27.
What drove Haemonetics's revenue change in Q2 FY27?
Apheresis +$23.0M (+13%); MedSurg +$7.5M (+5%).